Skin biotinIt is a clinical-stage biotechnology company that develops targeted topical therapies for the root causes of skin diseases and has raised US$28 million in A2 round of financing.It also acquired clinical-stage biotech companies Chromatin, The company is developing a topical melanin production inhibitor as a first-in-class treatment for skin whitening, melasma and other skin diseases. As part of these new developments, DermBiont has appointed Dr. Emma Taylor as Chief Medical Officer. Dr. Taylor is a dermatologist certified by the committee.
“We are very happy to welcome Chromaderm and his team to DermBiont,” said Dr. Karl Beutner, co-founder and CEO of DermBiont. “The topical small molecule drugs being developed by Chromaderm are very suitable for DermBiont’s product portfolio, which focuses on targeted topical treatment of skin diseases with a clear mechanism of action.”
Excessive melanin production is the root cause of many common skin diseases, including melasma, solar freckles (dark spots), and hyperpigmentation after inflammation. These diseases are most common in Hispanics, African Americans, and Asians, and mainly affect women. Melasma affects approximately 5 million people in the United States, and the prevalence in some populations is as high as 40%. The current treatment effect for these diseases is very small, not specific, and there are major safety issues.
As part of the transaction, Jeni Lee, head of Pivotal Life Sciences, joined DermBiont’s board of directors. In addition to Pivotal Life Sciences, this round of financing also includes participation from Viking Global Investors, Olive Tree Capital, Toba Capital, Civilization Ventures and other biotechnology investors.
To read more, click here.
This U.S. Food and Drug Administration A draft digital health technology guideline for remote data collection in clinical research has been released. The guidelines provide clinical trial sponsors, researchers, and other stakeholders with advice on using digital health technologies to obtain data remotely from clinical survey participants evaluating medical products. Digital health technology can take the form of hardware and/or software, which can be used to collect health-related information from research participants and transmit this information to research investigators and/or other authorized parties to evaluate the safety of medical products And effectiveness. The deadline for submission of comments on the draft guidelines is March 23, 2022.
To read more, click here.
Guinness HealthThe revenue cycle automation and decision support platform established in 2020 has completed a $8 million Series A financing led by Ensemble Health Partners and in cooperation with Caduceus Capital Partners.
As part of the transaction, Ensemble Health Partners’ executive vice president of strategy and corporate development Jim Gaffney and Caduceus Capital Partners’ venture partner Sue Tyler will serve on the Janus Health board of directors.
Janus Health co-founder and CEO Brendan Downing said: “Several factors such as labor shortages, reduced reimbursements and a more stable IT environment are creating a mature opportunity to change the revenue cycle through artificial intelligence and automation.” “Janus Health Providing timely services can have a major impact on health systems struggling to meet these rising collection costs and reimbursement challenges.”
To read more, click here.
Encourage healthA health technology company focusing on objective doctor performance analysis has completed a US$20 million Series B financing led by Echo Health Ventures. Embold Health was established on the premise that only when all service targets can obtain objective clinical performance indicators, can the cost and quality of medical care be significantly improved.
To read more, click here.
MedCity News is currently accepting applications from healthcare startups. As part of the INVEST conference, our INVEST Pitch Perfect competition is held in collaboration with the Central American Healthcare Investor Network (MHIN). The conference will be held in Chicago from March 28th to 30th. Held at the Ritz-Carlton.
Categories include:
- Pharmaceutical Technology
- Diagnosis 2.0
- Remote patient monitoring and smart devices
- Nursing coordination and value-based care.
Entrepreneurs will introduce their company to a group of investors and then answer their questions. The winner of each category will receive a profile of the news team in MedCity News.
The deadline for application is January 15. To learn more and apply, click here.
picture: Aquindo, Getty Images
